This document is a publication of a new patent application (US20260085126A1) filed with the USPTO on August 27, 2025. The application describes agonistic binding agents that target receptors within the TNF superfamily, specifically those binding to at least two different receptors. The abstract highlights the potential use of these agents in medicine, as well as related nucleic acid molecules, cells, pharmaceutical compositions, and kits.

This filing represents a new intellectual property disclosure. While patent applications themselves do not impose direct regulatory obligations on companies, they signal innovation and potential future product development in the pharmaceutical and biotechnology sectors. Companies operating in these areas, particularly those involved in drug discovery and development related to immune response or inflammatory conditions, should be aware of this application as it may indicate emerging technologies or competitive research directions.